|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
WednesdayTeriflunomide, an oral dihydro-orotate dehydrogenase inhibitor
NEW DRUGS: Teriflunomide Reduces Active Lesions in MS Patients:
"Treatment with teriflunomide, an oral dihydro-orotate dehydrogenase inhibitor, reduces disease activity with a trend towards fewer relapses in patients with MS according to the results of a phase II trial conducted by North American and European investigators. Lead researcher Dr. Paul W. O'Connor told Reuters Health: 'These findings are exciting in that they move us one step further to developing something that all MS patients on therapy want: an effective oral treatment.' All current MS drugs require administration by injection. However, teriflunomide, which can be given orally, has shown promise in animal models of autoimmune disease, Dr. O'Connor of St. Michael's Hospital, Toronto and colleagues note in the March 28th issue of Neurology....." |